1. Home
  2. SOPA vs SCYX Comparison

SOPA vs SCYX Comparison

Compare SOPA & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Society Pass Incorporated

SOPA

Society Pass Incorporated

HOLD

Current Price

$2.22

Market Cap

23.0M

Sector

Technology

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.80

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOPA
SCYX
Founded
2018
1999
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.0M
26.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
SOPA
SCYX
Price
$2.22
$0.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$22.50
$3.00
AVG Volume (30 Days)
15.0M
513.5K
Earning Date
11-14-2025
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,227,427.00
$2,932,000.00
Revenue This Year
$2.43
$170.77
Revenue Next Year
$71.20
$286.38
P/E Ratio
N/A
N/A
Revenue Growth
4.65
N/A
52 Week Low
$0.64
$0.57
52 Week High
$6.75
$1.31

Technical Indicators

Market Signals
Indicator
SOPA
SCYX
Relative Strength Index (RSI) 48.34 70.59
Support Level $2.12 $0.63
Resistance Level $2.78 $0.87
Average True Range (ATR) 0.30 0.05
MACD -0.09 0.02
Stochastic Oscillator 8.05 71.12

Price Performance

Historical Comparison
SOPA
SCYX

About SOPA Society Pass Incorporated

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: